Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 156

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part II, Item 1A
Chunk 156
---
urchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions.

Refer to Note 11, Stockholders’ Equity, to our condensed consolidated financial statements included herein for more information on our share repurchases.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  60

Item 5. OTHER INFORMATION

Rule 10b5-1 Trading PlansThe following table shows the “Rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” (as each term is defined in Item 408(a) of Regulation S-K) adopted by our directors and executive officers during the quarter ended September 30, 2025. No trading arrangements were terminated by our directors and executive officers during the quarter ended September 30, 2025. Trading ArrangementName and PositionActionDateRule10b5-1*Non-Rule10b5-1**Total Number ofShares to be SoldExpirationDateJonathan SloninChief Medical OfficerAdopt8/12/2025x10,2618/28/2026Kristen WilliamsChief Administrative Officer and SecretaryAdopt9/10/2025xTo Be Determined (1)6/5/2026 * Intended to satisfy the affirmative defense of Rule 10b5-1(c).** Not intended to satisfy the affirmative defense of Rule 10b5-1(c).(1) The aggregate number of shares to be sold pursuant to the trading arrangements listed above are dependent on, among other things, sale prices under the trading arrangements and the amount of tax withholding required upon the vesting of restricted stock units, and, therefore, is indeterminable at this time.

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  61

Item 6. EXHIBITS

The exhibits listed below are filed or furnished as part of this report.

Exhibit NumberDescription10.1Credit Agreement, dated as of July 3, 2025, by and among Pacira BioSciences, Inc.,